To evaluate the immunogenicity of inactivated SARS coronavirus (SARS-CoV), three groups of rabbits were immunized three times at 2-week intervals with inactivated vaccine + adjuvant, adjuvant, and normal saline respectively. Eight batchs of serum were sampled from the auricular vein at day 7 to day 51, and specific IgG antibody titers and neutralizing antibody titers were detected by indirect ELISA and micro-cytopathic effect neutralizing test. Antibody specificity was identified by proteinchip assay.
established a solid bases for effective control and ultimate eradication of the disease (3, 4, 8, 9) . The genomes of SARS-CoV has been mapped and some important structural and functional proteins have been determined, but many features regarding the nosogenesis, the antigenicity and the immuogenicity of SARS-CoV still remain indistinct (2, 7, 10, 17) .
Vaccines play a crucial role in the control of infectious diseases. Previous experiences on human antiviral vaccines indicated that inactivated vaccines are much easier to develop and hold more potential.
To investigate a SARS inactivated vaccine, effectiveness and safety of vaccine are two important aspects. Our efforts have focused on the investigation of the immunogenicity and safety of inactivated SARS-CoV on animals such as mice, rabbits, pigs, and horses (15, 16) . This paper reports the specific antibody kinetics and the histopathological changes in rabbits immunized with inactivated SARS-CoV, which a view to gaining some insight towards the development of SARS inactivated vaccine.
MATERIALS AND METHODS

SARS-CoV strain
SARS-CoV F69 strain (GenBank AY313906) was isolated from the samples of a onset of SARS patient in Guangdong province, China in 2003, and was screened out as the vaccine strain (5, 18) . Vero E6 cells were cultivated routinely with MEM medium containing no bovine serum, followed by infection with F69 strain virus. After the cytopathic effect (CPE) reached more than 75%, the cell suspension was frozen and thawed three times, and stored at -7 .
The titer of virus suspension was 10 6.7 TCID 50 /mL determined with micro-plate CPE method.
Vaccine preparation
Large-scale cultivated F69 virus suspension was inactivated with 0.4% formaldehyde (v/v) for 24 h at 37 , and the inactivation efficiency (100%) was precisely identified (6) . After centrifugation at 4 000× g for 30 min to remove precipitate, the virus supernatant 
Animal immunization
Adult New Zealand rabbits (male, 2.0-2.5 kg) were randomly divided into 3 groups (n=4): the experimental group (G1, immunized with vaccine + adjuvant), the adjuvant group (G2, immunized just with adjuvant), and the control group (G3, injected with 0.9% NaCl sulution). Rabbits all were inoculated 3 times. The immune protocol was shown in Table 1 .
Eight batches of blood were sampled from the auricular vein at day 7, 14, 21, 28, 35, 38, 42 and 51.
Serum was separated by centrifugation at 2 500×g for 10 min and stored at -20 .
Enzyme-linked immunosorbent assay
The titer of serum specific IgG antibody was measured 
Neutralizing test
Neutralizing antibody titer was determined by the micro-cytopathic effect (CPE) neutralizing test according to the modified protocol for polio antibodies (13) . The serum was diluted into two-fold serial dilutions with MEM maintenance medium, then mixed with an equal volume of 100 TCID 50 active SARS-CoV and incubated at 37 for 60 min. After neutralization, the pretreated mixtures were successively added into Vero E6 cell monolayers in a microtiter plate (100 μL/well); wells for normal cell control were added into 100 μL maintenance medium, and wells for virus control were added into unneutralized virus. The plate was incubated at 37 in 5% 
Histopathological detection
On day 51 after the first vaccination, all the rabbits were sacrified, then autopsied to gain the lung, liver, heart, spleen, kidney and testis. Tissues of the sampled organs were fixed in 10% neutral-buffered formalin and routinely processed for paraffin embedding. Serial 4 m sections were cut from each block. The tissue slices were stained with hemotoxylin and eosin dyes (H&E), and detected with photomicrography.
RESULTS
Kinetics of specific IgG antibody titers
Antibody titers of eight batches of serum samples from day 7 to day 51 were measured by indirect ELISA (Fig.1) . The specific IgG antibodies in experimental group (G1) were detectable even on day 7, and rapidly reached a peak value of 1:40 960 on day 35. After day 35, the antibody levels had a gradual decline. On day 51, the specific IgG antibody titers remained at about 1:12 800. In the adjuvant group (G2) and control group (G3), the sera all were negative.
Variation of neutralizing antibody titers
The inactivated SARS-CoV antigen elicited potent neutralizing antibody responses (Fig. 2) . On day 14, neutralizing antibody was detected in the experimental titers. Six batches of rabbit serum were sampled from day 14 to day 51 in three test groups (G1, G2, G3). Neutralizing antibody titers were determined by micro-cytopathic effect neutralizing test and are shown on a logarithmic scale.
group, then followed a rapid increase. Four weeks after the first vaccination, neutralizing titer reached a peak value of 1:2 560. In the subsequent four weeks, neutralizing antibody titers remained or declined slightly despite a third vaccination being administered at this stage, but it was negative in the adjuvant group and control group.
Specificity identification of the antiserum
Two sets of antiserum samples from experimental group and one normal serum were analyzed on day 33
with the SARS protein chip. The representative profiles are shown in Fig. 3 . Antibodies of the 2 stocks of antiserum showed specific interactions with the known recombinant SARS-CoV proteins, including the N, 3CL and four S protein segments. The normal serum showed a negative result.
Histopathological changes of rabbit tissues
In experimental group (G1), no obvious histopathological changes were detected in H&E stained tissue slides of the heart, spleen, kidney, testis, but the liver tissues had slight histopathological changes, while the 
